Absci to present at three major healthcare investor conferences in Nov-Dec 2026

Absci Corporation, a clinical-stage biopharmaceutical company using AI to design new therapeutics, announced it will participate in three upcoming investor conferences: Guggenheim Healthcare Innovation (Nov 10), Jefferies Global Healthcare (Nov 18), and Evercore Healthcare (Dec 1). These events will feature fireside chats accessible via live webcast on Absci's investor site. Absci is advancing AI-designed drugs including ABS-201, targeting hair regrowth and endometriosis, highlighting its innovative approach in drug discovery and potential market impact.

Absci Corporation has a market cap of $1.62 billion and an enterprise value of $1.43 billion as of Oct 27, 2026 19:11 WIB on Pluang. The stock price is USD 9.60, showing a 1.59% increase in the last day with a trading volume of 3,360,259 shares. This trading activity reflects active investor interest shortly before the company’s participation in multiple upcoming healthcare investor conferences.